Interindividual changes in volume of distribution of cefazolin in newborn infants and its prediction based on physiological pharmacokinetic concepts.
暂无分享,去创建一个
[1] P. C. Walker. Neonatal Bilirubin Toxicity , 1987, Clinical pharmacokinetics.
[2] M. Tsunoo,et al. Pharmacokinetics and protein binding of cefazolin and cephalothin in patients with cirrhosis. , 1986, The Journal of antimicrobial chemotherapy.
[3] T. Terasaki,et al. Physiologically based pharmacokinetic model for cefazolin in rabbits and its preliminary extrapolation to man. , 1985, Drug metabolism and disposition: the biological fate of chemicals.
[4] T. Terasaki,et al. Physiologically Based Pharmacokinetic Model for β-Lactam Antibiotics I: Tissue Distribution and Elimanation Rates , 1983 .
[5] P. McNamara,et al. Fraction unbound in interstitial fluid. , 1983, Journal of pharmaceutical sciences.
[6] P. Morselli,et al. Clinical Pharmacokinetics in Newborns and Infants , 1980 .
[7] S Oie,et al. Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.
[8] R. F. Chen,et al. Removal of fatty acids from serum albumin by charcoal treatment. , 1967, The Journal of biological chemistry.
[9] B. Friis‐Hansen. Body water compartments in children: changes during growth and related changes in body composition. , 1961, Pediatrics.
[10] P. McNamara,et al. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding II. Physiological significance , 2004, European Journal of Clinical Pharmacology.